Pay for Delay, Dodd-Frank, Broker Bonuses: Compliance

The U.S. Supreme Court agreed to take up a multibillion-dollar fight between the drug industry and federal antitrust enforcers, a case that may determine how quickly low-price generic medicines reach the market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.